Rubicon Research Share Price Target 2026 Analyst Forecast Bull and Bear Case

Rubicon Research (NSE: RUBICON) is a Pharmaceutical CDMO and Formulations company trading at Rs 1,408 with a market capitalisation of Rs 23,037 crore. Analysts have set the Rubicon Research share price target at Rs 1,700 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Rubicon Research Share Price Target 2026: Key Takeaways

• Rubicon Research share price target 2026: Rs 1,700 (20% upside from CMP Rs 1,408)
• Bull case: Rs 2,050 | Bear case: Rs 1,150
• Ticker: RUBICON | Sector: Pharmaceutical CDMO and Formulations | MCap: Rs 23,037 crore
• 52W range: Rs 570.75 to Rs 1,469 | PE: 25x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Rubicon Research Company Overview

Rubicon Research (NSE: RUBICON) is a Mumbai-based pharmaceutical CDMO specialising in controlled-release oral solid dosage forms, orally disintegrating tablets, and modified release drug delivery for the US, Europe, and Japan markets. At CMP Rs 1,408 against a 52 week range of Rs 570.75 to Rs 1,469, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 23,037 crore with trailing PE of 25x. Compared to peers in CDMO like Suven Pharma and Piramal Pharma, Rubicon Research is positioned as a potential re-rating candidate toward the Rs 1,700 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	RUBICON
Sector	Pharmaceutical CDMO and Formulations
CMP (2026)	Rs 1,408
52 Week High	Rs 1,469
52 Week Low	Rs 570.75
Market Cap	Rs 23,037 crore
Trailing PE	25x
12-Month Analyst Target	Rs 1,700
Bull Case Target	Rs 2,050
Bear Case Target	Rs 1,150

Why Is the Rubicon Research Share Price Target Set at Rs 1,700 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Rubicon Research share price target of Rs 1,700 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 1,408.

Structural Sector Tailwinds in Pharmaceutical CDMO and Formulations

The Pharmaceutical CDMO and Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Rubicon Research’s position among peers in CDMO like Suven Pharma and Piramal Pharma creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 2,050 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Rubicon Research’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,700 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Rubicon Research’s Pharmaceutical CDMO and Formulations operations, improving the probability of achieving the Rs 1,700 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, Rubicon Research is positioned as a beneficiary of institutional reallocation toward the Rs 2,050 bull case over the medium term.

Rubicon Research Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Rubicon Research Share Price Target

Near-term support for Rubicon Research is anchored close to the 52 week low of Rs 570.75. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 1,408.

12-Month Rubicon Research Share Price Target 2026

The 12-month Rubicon Research share price target 2026 is Rs 1,700, implying approximately 20 percent upside from CMP Rs 1,408. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Rubicon Research Share Price Target: FY27 to FY28

The long term Rubicon Research share price target for FY27 to FY28 is Rs 2,050 in the bull case, requiring full earnings delivery, re-rating among peers in CDMO like Suven Pharma and Piramal Pharma, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Rubicon Research in 2026

Bull Case Rubicon Research Share Price Target: Rs 2,050

The bull case Rubicon Research share price target of Rs 2,050 materialises when FY27 earnings beat analyst estimates, Pharmaceutical CDMO and Formulations tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 1,408.

Bear Case Rubicon Research Share Price Target: Rs 1,150

The bear case Rubicon Research share price target of Rs 1,150 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 570.75.

Scenario	Target	Key Conditions
Bull Case	Rs 2,050	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 1,700	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 1,150	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Rubicon Research 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Rubicon Research share price target of Rs 1,700, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,700 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical CDMO and Formulations Peers

Intensifying competition from peers in CDMO like Suven Pharma and Piramal Pharma could compress Rubicon Research’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,700 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Rubicon Research

Check the Univest Screener for live data

Before considering any investment based on the Rubicon Research share price target of Rs 1,700, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical CDMO and Formulations sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Rubicon Research (NSE: RUBICON) with full regulatory protection. Study the competitive landscape among peers in CDMO like Suven Pharma and Piramal Pharma before executing any position.

Plan your entry using the 52 week low of Rs 570.75 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,700 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Rubicon Research’s live share price and receive daily stock recommendations.

FAQs on Rubicon Research Share Price Target 2026

What is the Rubicon Research share price target for 2026?

Ans. The Rubicon Research share price target 2026 is Rs 1,700, implying approximately 20 percent upside from CMP Rs 1,408. Bull case is Rs 2,050, bear case is Rs 1,150.

What was the Rubicon Research share price target for 2025?

Ans. The 2025 price objective for Rubicon Research was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,700, reflecting FY27 growth potential from CMP Rs 1,408.

Is Rubicon Research a good investment at Rs 1,408?

Ans. At Rs 1,408, Rubicon Research offers potential upside toward Rs 1,700 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Rubicon Research share price target 2026?

Ans. Key risks to the Rubicon Research share price target of Rs 1,700 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical CDMO and Formulations. Monitoring quarterly results is essential.

What is the 52 week high and low of Rubicon Research?

Ans. The 52 week high of Rubicon Research is Rs 1,469 and the 52 week low is Rs 570.75. At CMP Rs 1,408, the stock offers potential upside toward the Rs 1,700 price objective.

What are the main growth catalysts for Rubicon Research in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical CDMO and Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Rubicon Research compare to its peers?

Ans. Rubicon Research operates in Pharmaceutical CDMO and Formulations alongside peers in CDMO like Suven Pharma and Piramal Pharma. At CMP Rs 1,408 with MCap Rs 23,037 crore, it is a potential re-rating candidate toward the Rubicon Research share price target of Rs 1,700 on FY27 delivery.

What is the Rubicon Research share price target for 2027?

Ans. The long-term Rubicon Research share price target for FY27 to FY28 is Rs 2,050 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.